Clinical Trial Update: DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating DNX-2401 in combination with interferon gamma for recurrent glioblastoma or gliosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• DNX-2401 (Delta-24-RGD)
• Interferon-gamma (interferon gamma)

Snippet

Sponsor: DNAtrix, Inc. | Conditions: Glioblastoma or Gliosarcoma | Phase 1 | Status: COMPLETED